Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

Pfizer

Status and phase: Completed; Phase 1

Conditions: Rheumatoid Arthritis

Treatments: Drug: CP-690,550 (tasocitinib)

Study type: Interventional

Funder types: Industry

Identifiers

NCT01262118

A3921130

Details and patient eligibility

About

The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).

Enrollment: 69 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older

Exclusion criteria

• Pregnant or lactating women
• Clinically significant systemic disease (other than RA for RA arm)
• Use of lipid-regulating agents

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

69 participants in 2 patient groups

CP-690,550 (tasocitinib) 10 mg twice daily (BID)

Experimental group

Treatment:

Drug: CP-690,550 (tasocitinib)

Healthy Volunteers

No Intervention group

Description:

No intervention